Granada Hills, California–(Newsfile Corp. – May 24, 2021) – Pervasip Corp. (OTC Pink: PVSP) is pleased to announce that its wholly owned subsidiary Transcendence Age Corp. (“Transcendence”) and its affiliate Vics Consulting Group Inc. are working to conclude a successful trip to South Korea.
Kyong Lae Kim, the executive director of International Relations for Transcendence, has been working with government officials, landowners, and private corporations in South Korea in conjunction with the study of CBD for medical use in the treatment of chronic pain and various cancers. Additionally, Mr. Kim has submitted a proposal for a 100-acre CDB farm.
Cesar Herrera, President of Transcendence, said, “Our affiliate is now registered with the Korean FDA to study CBD, and we hope to obtain approval for psilocybin research. In addition to the research, we expect to provide consulting work, financial projections and build-out plans for farmers. Our research can be more effective if we diligently work with government officials and landowners and provide them with the seeds that we believe are the most constructive.”
“The planning work we are doing with a CBD project in Uzbekistan has been helpful to projects we are proposing in other parts of Asia,” continued Mr. Herrera. “We are eagerly waiting for a license to be issued so that we can proceed with the Uzbekistan project. We believe the license will be issued in June.”
To further enhance revenues and to better understand the dosage, efficacy and safety of CBD and psilocybin usage, Mr. Kim has introduced Pervasip to a biotech opportunity. Pervasip is considering the purchase of a biotech lab to enhance its analysis and generate additional revenues.
Further updates will be announced regarding CBD, psilocybin, and the biotech lab after Mr. Kim returns to the United States.
About Pervasip Corp.
Pervasip formed Transcendence to study and provide health and wellness consulting for psilocybin treatments. Research has shown that psilocybin has potential to treat a wide range of behavioral and psychiatric disorders. Transcendence is comprised of an established team of professionals, incorporating infrastructure specialists, growing specialists, and holistic medicinal specialists. Several of its team members also have an expertise in a variety of CBD products.
Please email Investor Relations with any questions at firstname.lastname@example.org or call 855-464-2535 extension 1.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include those that use forward-looking terminology, such as the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “hope'” “project,” “plan,” “will,” “shall,” “should,” and similar expressions, including when used in the negative. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84972